lanabecestat

Small moleculeexperimental

Lanabecestat is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the buildup of beta-amyloid and may help slow or stop the progression of Alzheimer's disease. — Wikipedia

Clinical trial activity

12 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
2
Phase 3
3
Phase 4
0

Earliest trial started Sep 1, 2014 (NCT02245737)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1
Mol. weight
412.54 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lanabecestat
  • lanabecestat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03545087Phase 1Jun 30, 2018AstraZeneca, Eli Lilly
NCT03506399Phase 1Jun 30, 2018AstraZeneca, Eli Lilly
NCT03499041Phase 1Jun 30, 2018AstraZeneca, Eli Lilly
NCT03222427Phase 1Jan 15, 2018AstraZeneca, Eli Lilly
NCT02972658Phase 3Mar 15, 2017AstraZeneca, Eli Lilly
NCT03019549Phase 1Jan 12, 2017AstraZeneca, Eli Lilly
NCT02783573Phase 3Jul 1, 2016AstraZeneca, Eli Lilly
NCT02663128Phase 1Jan 1, 2016AstraZeneca, Eli Lilly
NCT02568397Phase 1Oct 1, 2015AstraZeneca, Eli Lilly
NCT02540668Phase 1Sep 1, 2015AstraZeneca, Eli Lilly
NCT02406261Phase 1Apr 1, 2015AstraZeneca, Eli Lilly
NCT02245737Phase 2/Phase 3 (Phase 3)Sep 1, 2014AstraZeneca, Eli Lilly
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit12022014
Eli LillyFor profit121222014
2 organizations
Page 1 / 1